Citadel Advisors’s Opus Genetics IRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $550K | Sell |
120,900
-59,821
| -33% | -$207K | ﹤0.01% | 9066 |
|
|
2025
Q4 | $363K | Buy |
180,721
+67,305
| +59% | +$137K | ﹤0.01% | 9738 |
|
|
2025
Q3 | $187K | Buy |
+113,416
| New | +$141K | ﹤0.01% | 11327 |
|
|
2025
Q2 | – | Sell |
-67,877
| Closed | -$62.9K | – | 15649 |
|
|
2025
Q1 | $66.6K | Sell |
67,877
-107,896
| -61% | -$121K | ﹤0.01% | 11980 |
|
|
2024
Q4 | $209K | Buy |
175,773
+88,954
| +102% | +$102K | ﹤0.01% | 10377 |
|
|
2024
Q3 | $114K | Buy |
86,819
+72,721
| +516% | +$112K | ﹤0.01% | 10951 |
|
|
2024
Q2 | $21.6K | Sell |
14,098
-65,432
| -82% | -$113K | ﹤0.01% | 12565 |
|
|
2024
Q1 | $160K | Buy |
79,530
+64,255
| +421% | +$163K | ﹤0.01% | 10667 |
|
|
2023
Q4 | $46K | Buy |
+15,275
| New | +$45.2K | ﹤0.01% | 11859 |
|
|
2023
Q2 | – | Sell |
-3,946
| Closed | -$18.7K | – | 15391 |
|
|
2023
Q1 | $14.8K | Sell |
3,946
-34,066
| -90% | -$122K | ﹤0.01% | 13283 |
|
|
2022
Q4 | $134K | Buy |
+38,012
| New | +$100K | ﹤0.01% | 10784 |
|
|
2022
Q3 | – | Sell |
-16,458
| Closed | -$35.5K | – | 13789 |
|
|
2022
Q2 | $32K | Buy |
+16,458
| New | +$37.4K | ﹤0.01% | 12187 |
|
|
2021
Q4 | – | Sell |
-57,502
| Closed | -$231K | – | 14942 |
|
|
2021
Q3 | $296K | Buy |
57,502
+43,245
| +303% | +$199K | ﹤0.01% | 11092 |
|
|
2021
Q2 | $75K | Buy |
+14,257
| New | +$70.8K | ﹤0.01% | 13117 |
|
|
2019
Q2 | – | Sell |
-616
| Closed | -$15K | – | 9978 |
|
|
2019
Q1 | $15K | Sell |
616
-39
| -6% | -$1.29K | ﹤0.01% | 9112 |
|
|
2018
Q4 | $29K | Buy |
+655
| New | +$38.3K | ﹤0.01% | 8632 |
|
|
2018
Q3 | – | Sell |
-348
| Closed | -$24K | – | 9787 |
|
|
2018
Q2 | $24K | Buy |
+348
| New | +$30.6K | ﹤0.01% | 8609 |
|
|
2018
Q1 | – | Sell |
-390
| Closed | -$38K | – | 8885 |
|
|
2017
Q4 | $38K | Buy |
+390
| New | +$39.6K | ﹤0.01% | 7708 |
|
|
2017
Q2 | – | Sell |
-163
| Closed | -$40K | – | 8187 |
|
|
2017
Q1 | $40K | Buy |
+163
| New | +$21.1K | ﹤0.01% | 7101 |
|
|
2016
Q3 | – | Sell |
-274
| Closed | -$33K | – | 7877 |
|
|
2016
Q2 | $33K | Buy |
+274
| New | +$38.4K | ﹤0.01% | 6504 |
|
|
2016
Q1 | – | Sell |
-35
| Closed | -$6K | – | 8148 |
|
|
2015
Q4 | $6K | Sell |
35
-45
| -56% | -$9.57K | ﹤0.01% | 8416 |
|
|
2015
Q3 | $20K | Buy |
80
+14
| +21% | +$3.8K | ﹤0.01% | 8154 |
|
|
2015
Q2 | $19K | Buy |
+66
| New | +$22.4K | ﹤0.01% | 8190 |
|
|
2015
Q1 | – | Sell |
-31
| Closed | -$10K | – | 8918 |
|
|
2014
Q4 | $10K | Sell |
31
-35
| -53% | -$12.1K | ﹤0.01% | 8139 |
|
|
2014
Q3 | $26K | Sell |
66
-89
| -57% | -$32.1K | ﹤0.01% | 7292 |
|
|
2014
Q2 | $65K | Buy |
+155
| New | +$70.5K | ﹤0.01% | 6555 |
|
|
2013
Q4 | – | Sell |
-88
| Closed | -$19K | – | 7194 |
|
|
2013
Q3 | $19K | Buy |
88
+28
| +47% | +$6.53K | ﹤0.01% | 6238 |
|
|
2013
Q2 | $13K | Buy |
+60
| New | +$10.3K | ﹤0.01% | 6176 |
|
Other funds holding IRD
CP
BCM
VCM
BCM
ACM
PA
Citadel Advisors's IRD Position: Q1 2026 in Review
Citadel Advisors reduced its Opus Genetics (IRD) stake by 33% in Q1 2026, selling an estimated $207K and leaving 120,900 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #9066.
Citadel Advisors first reported a position in IRD in Q2 2013 and has held it in 28 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.
- Citadel Advisors held 120,900 shares of Opus Genetics worth $550K as of Q1 2026.
- Citadel Advisors sold 59,821 Opus Genetics shares in Q1 2026, an estimated $207K.
- Opus Genetics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9066 holding.
- Citadel Advisors first reported a position in Opus Genetics in Q2 2013 and has held it in 28 quarters since.
- 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.